Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24029303 | 0.85 | KDM4E (0.31) | KDM4EALDH1A1CYP3A4GABRB3OPRD1 | |
| SCHEMBL20239773 | 0.77 | PGR (0.39) | ALDH1A1LMNA | |
| SCHEMBL25560572 | 0.77 | PGR (0.39) | ALDH1A1LMNA | |
| SCHEMBL24029214 | 0.77 | PGR (0.39) | ALDH1A1LMNA | |
| SCHEMBL24740337 | 0.73 | HSD11B1 (0.31) | KDM4EALDH1A1CYP3A4GABRB3OPRD1 | |
| SCHEMBL24029106 | 0.72 | ACE (0.31) | ALDH1A1CYP3A4 | |
| SCHEMBL26644809 | 0.69 | KDM4E (0.35) | KDM4EALDH1A1CYP3A4GABRB3OPRD1 | |
| SCHEMBL23836578 | 0.68 | CCR2 (0.39) | KDM4EALDH1A1CYP3A4GABRB3OPRD1 | |
| SCHEMBL26644807 | 0.68 | KDM4E (0.31) | KDM4EALDH1A1CYP3A4GABRB3OPRD1 | |
| SCHEMBL24019608 | 0.67 | PSMB5 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11524940-B1 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2022-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524940-B1 | Inhibitors of cysteine proteases and methods of use thereof | CTRL, CTSV, CTSL | KDM4E 2930/4885ALDH1A1 2252/4885CYP3A4 944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.